Adverum Biotechnologies, Inc.

20 articles with Adverum Biotechnologies, Inc.

• 

  Biotech Companies Continue to Shake Up Leadership with New Appointments

  5/8/2018

  There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
• 

  Alder CEO Is Stepping Down

  3/21/2018

  Alder BioPharmaceuticals announced that Randall Schatzman, the company’s president, chief executive officer and director, will be stepping down.

• Adverum Biotechnologies Announces Proposed Public Offering of Common Stock

  2/8/2018

  The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

• Adverum Biotechnologies Announces Pricing of $60M Public Offering of Common Stock

  2/8/2018

  Adverum Biotechnologies today announced the pricing of an underwritten public offering of 8,888,900 shares of its common stock at a price to the public of $6.75 per share.

• Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

  1/26/2018

  The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.

• Adverum Biotechnologies Provides 2018 Outlook

  1/4/2018

  Accelerating pipeline development in 2018 after transforming into clinical-stage company in 2017.

• Adverum Biotechnologies Doses First Patient in the ADVANCE Phase I/II Clinical Trial of ADVM-043 for A1AT Deficiency

  12/28/2017

  The ADVANCE clinical trial is designed to evaluate the safety and protein expression following a single administration of ADVM-043, Adverum’s novel gene therapy candidate.

• Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase I/II Clinical Trial for A1AT Deficiency

  12/5/2017

  The ADVANCE clinical trial is designed to evaluate the safety and protein expression following a single administration of ADVM-043, Adverum’s novel gene therapy candidate.

• Adverum Biotechnologies Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  11/9/2017

  Cash, cash equivalents and marketable securities were $186.6 million as of September 30, 2017, compared to $197.4 million as of June 30, 2017 and $222.2 million as of December 31, 2016.

• Adverum Biotechnologies Appoints Linda Neuman, M.D. As Vice President, Clinical Development

  10/3/2017

• Adverum Biotechnologies Presents Updated Preclinical Data On ADVM-022 In Wet AMD At The 2017 Targeting Ocular Disorders Conference

  9/28/2017

• Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. To Board Of Directors

  9/8/2017

• Adverum Biotechnologies Reports Second Quarter 2017 Financial Results And Provides Update

  8/9/2017

• Adverum Biotechnologies Announces Appointment Of Athena Countouriotis, M.D. As SVP And Chief Medical Officer

  6/20/2017

• Adverum Biotechnologies Reports First Quarter 2017 Financial Results And Provides Update

  5/10/2017

• Adverum Biotechnologies Appoints Richard N. Spivey, Pharm.D., Ph.D. To Board Of Directors

  4/20/2017

• Adverum Biotechnologies Appoints Patrick Machado, J.D. To Board Of Directors

  3/15/2017

• Synpromics Announces Expansion Of Research Collaboration With Adverum Biotechnologies

  12/7/2016

• Meet Amber Salzman, the Female CEO to Helm Bay Area's Adverum Biotechnologies

  10/17/2016

• Adverum Biotechnologies Appoints Leone Patterson As Chief Financial Officer

  6/14/2016